Comparative Pharmacology
Head-to-head clinical analysis: ENSTILAR versus HEMSOL HC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSTILAR versus HEMSOL HC.
ENSTILAR vs HEMSOL-HC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSTILAR is a combination of calcipotriene (a vitamin D analog) and betamethasone dipropionate (a corticosteroid). Calcipotriene binds to vitamin D receptors, modulating cell proliferation and differentiation. Betamethasone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation and immune response.
Apply to affected area once daily for up to 4 weeks. Maximum 100 g/day or 30 g/week. Not for use on face, axillae, or groin.
Intravenous: 100 mg hydralazine hydrochloride (equivalent to 80.5 mg hydralazine base) administered over 30 minutes, every 6 hours as needed, for a maximum of 48 hours. Oral: 10–50 mg every 6 hours, adjusted based on response.
None Documented
None Documented
Calcipotriol: terminal half-life ~12 hours. Betamethasone dipropionate: terminal half-life ~16-22 hours. Clinically, this supports once-daily application.
Terminal elimination half-life: 1.2-2.5 hours; clinically, dose adjustments needed in hepatic impairment due to prolonged clearance
Calcipotriol is primarily excreted via bile/feces (approximately 70% of absorbed dose). Betamethasone dipropionate is mainly excreted renally (60-70% as metabolites) and up to 20-30% via feces. For the combination, renal excretion of betamethasone metabolites predominates, with fecal excretion of calcipotriol.
Renal: >90% as unconjugated and conjugated metabolites; biliary/fecal: <10%
Category C
Category C
Topical Corticosteroid and Vitamin D Analog
Topical Corticosteroid